223 related articles for article (PubMed ID: 2511221)
1. Increased growth hormone pulse frequency in acromegaly.
Barkan AL; Stred SE; Reno K; Markovs M; Hopwood NJ; Kelch RP; Beitins IZ
J Clin Endocrinol Metab; 1989 Dec; 69(6):1225-33. PubMed ID: 2511221
[TBL] [Abstract][Full Text] [Related]
2. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
Gelato MC; Oldfield E; Loriaux DL; Merriam GR
J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
[TBL] [Abstract][Full Text] [Related]
3. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors.
Ho PJ; Jaffe CA; Friberg RD; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 1994 Jun; 78(6):1403-10. PubMed ID: 7911124
[TBL] [Abstract][Full Text] [Related]
4. Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly.
Ho PJ; Friberg RD; Barkan AL
J Clin Endocrinol Metab; 1992 Sep; 75(3):812-9. PubMed ID: 1517371
[TBL] [Abstract][Full Text] [Related]
5. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
[TBL] [Abstract][Full Text] [Related]
6. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
Losa M; Schopohl J; König A; Müller OA; von Werder K
J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone-releasing hormone infusion in patients with active acromegaly.
Losa M; Chiodini PG; Liuzzi A; König A; Müller OA; Schopohl J; von Werder K
J Clin Endocrinol Metab; 1986 Jul; 63(1):88-93. PubMed ID: 3086362
[TBL] [Abstract][Full Text] [Related]
9. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
10. Effects of sumatriptan on growth hormone releasing hormone-stimulated growth hormone secretion in acromegaly.
Cuttica CM; Sessarego P; Ponzani P; Falivene MR; Valenti S; De Martini D; Giusti M
Recenti Prog Med; 1997 Jun; 88(6):264-8. PubMed ID: 9233053
[TBL] [Abstract][Full Text] [Related]
11. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.
Hartman ML; Pincus SM; Johnson ML; Matthews DH; Faunt LM; Vance ML; Thorner MO; Veldhuis JD
J Clin Invest; 1994 Sep; 94(3):1277-88. PubMed ID: 8083369
[TBL] [Abstract][Full Text] [Related]
12. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
13. Lack of desensitization of adenomatous somatotrophs to growth-hormone releasing hormone in acromegaly.
Spada A; Elahi FR; Arosio M; Sartorio A; Guglielmino L; Vallar L; Faglia G
J Clin Endocrinol Metab; 1987 Mar; 64(3):585-91. PubMed ID: 3102543
[TBL] [Abstract][Full Text] [Related]
14. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy.
Hartman ML; Veldhuis JD; Vance ML; Faria AC; Furlanetto RW; Thorner MO
J Clin Endocrinol Metab; 1990 May; 70(5):1375-84. PubMed ID: 2335577
[TBL] [Abstract][Full Text] [Related]
15. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in acromegaly and type I diabetes mellitus.
Pietschmann P; Schernthaner G; Luger A
J Clin Endocrinol Metab; 1986 Aug; 63(2):389-93. PubMed ID: 3088023
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency.
Tzanela M; Guyda H; Van Vliet G; Tannenbaum GS
J Clin Endocrinol Metab; 1996 Jul; 81(7):2487-94. PubMed ID: 8675565
[TBL] [Abstract][Full Text] [Related]
17. Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients.
van der Klaauw AA; Pereira AM; van Thiel SW; Frolich M; Iranmanesh A; Veldhuis JD; Roelfsema F; Romijn JA
Clin Endocrinol (Oxf); 2007 Apr; 66(4):489-98. PubMed ID: 17371464
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly.
Kelijman M; Williams TC; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1988 Nov; 67(5):958-63. PubMed ID: 2903171
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone pulsatility in active and cured acromegalic subjects.
Semer M; Faria AC; Nery M; Salgado LR; Knoepfelmacher M; Wajchenberg BL; Liberman B
J Clin Endocrinol Metab; 1995 Dec; 80(12):3767-70. PubMed ID: 8530632
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
